Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH

Histopathology

Volumn 56, Issue 2, 2010, Pages 203-211

  Kirkegaard, Tove ^a,b,c   Witton, Caroline J ^b   Edwards, Joanne ^a   Nielsen, Kirsten Vang ^b   Jensen, Linda Boye ^a   Campbell, Fiona M ^a   Cooke, Timothy G ^a   Bartlett, John M S ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b AGILENT TECHNOLOGIES   (United States)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

AKT; Breast cancer; FISH; Genetic alterations; Prostate cancer

Indexed keywords

ESTROGEN RECEPTOR; GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; TAMOXIFEN;

AKT 1 GENE; AKT 2 GENE; AKT 3 GENE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 19; DISOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE DUPLICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

ANEUPLOIDY; ANIMALS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DELETION; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN;

MAMMALIA;

EID: 73449142838     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03467.x     Document Type: Article

References (50)

1. Murthy SS, Tosolini A, Taguchi T, Testa JR. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet. Cell Genet. 2000 88 38 40.
2. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999 13 2905 2927.
3. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol. Ther. 2002 93 243 251.
4. Thompson JE, Thompson CB. Putting the rap on Akt. J. Clin. Oncol. 2004 22 4217 4226.
5. Franke TF, Yang SI, Chan TO et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995 81 727 736.
6. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003 4 257 262.
7. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001 276 9817 9824.
8. Stoica GE, Franke TF, Moroni M et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003 22 7998 8011.
9. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, Edwards J. Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients. Br. J. Cancer 2008 98 1094 1101.
10. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997 91 231 241.
11. Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998 282 1318 1321.
12. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999 96 857 868.
13. Chen WS, Xu PZ, Gottlob K et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001 15 2203 2208.
14. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 2001 276 38349 38352.
15. Cho H, Mu J, Kim JK et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 2001 292 1728 1731.
16. Yang ZZ, Tschopp O, Hemmings-Mieszczak M et al. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J. Biol. Chem. 2003 278 32124 32131.
17. Yang ZZ, Tschopp O, Di-Poi N et al. Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol. Cell. Biol. 2005 25 10407 10418.
18. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell. Signal. 2002 14 381 395.
19. Kirkegaard T, Witton CJ, McGlynn LM et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 2005 207 139 146.
20. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin. Cancer Res. 2006 12 123 130.
21. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl Acad. Sci. USA 1987 84 5034 5037.
22. Sun M, Wang G, Paciga JE et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 2001 159 431 437.
23. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl Acad. Sci. USA 1996 93 3636 3641.
24. Cheng JQ, Godwin AK, Bellacosa A et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 1992 89 9267 9271.
25. Bellacosa A, de Feo D, Godwin AK et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995 64 280 285.
26. Nakatani K, Thompson DA, Barthel A et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 1999 274 21528 21532.
27. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005 16 797 803.
28. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008 68 6084 6091.
29. Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, Lee SH. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006 70 285 289.
30. Kanamori Y, Kigawa J, Itamochi H et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 2001 7 892 895.
31. Yuan ZQ, Sun M, Feldman RI et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000 19 2324 2330.
32. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin. Cancer Res. 2005 11 4835 4842.
33. Kirkegaard T, McGlynn LM, Campbell FM et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin. Cancer Res. 2007 13 1405 1411.
34. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005 23 7483 7490.
35. Bartlett JM, Munro AF, Cameron DA, Thomas JS, Prescott RJ, Twelves CJ. Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. 2008 26 5027 5035.
36. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res. Treat. 2003 77 109 114.
37. Arboleda MJ, Lyons JF, Kabbinavar FF et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003 63 196 206.
38. Zinda MJ, Johnson MA, Paul JD et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin. Cancer Res. 2001 7 2475 2479.
39. Bachman KE, Argani P, Samuels Y et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004 3 772 775. (Pubitemid 41351083)
40. Khan S, Kumagai T, Vora J et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int. J. Cancer 2004 112 407 410.
41. Yoshimoto M, Cutz JC, Nuin PA et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet. Cytogenet. 2006 169 128 137.
42. Yoshimoto M, Cunha IW, Coudry RA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br. J. Cancer 2007 97 678 685.
43. Bertram J, Peacock JW, Fazli L et al. Loss of PTEN is associated with progression to androgen independence. Prostate 2006 66 895 902.
44. Ried T, Just KE, Holtgreve-Grez H et al. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res. 1995 55 5415 5423.
45. O'Connell P, Fischbach K, Hilsenbeck S et al. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J. Natl Cancer Inst. 1999 91 1391 1397.
46. Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC, O'Connell P. Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 2001 61 3578 3580.
47. Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma. Hum. Mol. Genet. 2006 15 821 830.
48. Nexo BA, Vogel U, Olsen A et al. A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis 2003 24 899 904.
49. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004 6 117 127.
50. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007 12 395 402.